Citation: Kelsey M. McArthur, Amber M. Kay, Jenna A. Mosier, Joshua N. Grant, James A. Stewart, C. LaShan Simpson. Manipulating the Plasticity of Smooth Muscle Cells to Regulate Vascular Calcification[J]. AIMS Cell and Tissue Engineering, 2017, 1(3): 165-179. doi: 10.3934/celltissue.2017.3.165
[1] | Kee H, Cho S, Kim G, et al. (2014) Gallic acid inhibits vascular calcification through the blockade of BMP2-Smad 1/5/8 signaling pathway. Vasc Pharmacol 63: 71-78. doi: 10.1016/j.vph.2014.08.005 |
[2] | Kelly R, Tunin R, Kass D (1992) Effect of reduced aortic compliance on cardiac efficiency and contracticle function of in situ canine left ventricle. Circ Res 71: 490-502. doi: 10.1161/01.RES.71.3.490 |
[3] | Wayhs R, Zelinger A, Raggi P (2002) High coronary artery calcium scores pose an extremely elevated risk for hard events. J Am Coll Cardiol 39: 225-230. |
[4] | Mizobuchi M, Towler D, Slatopolsky E (2009) Vascular Calcifciation: The Killer of Patients with Chronic Kidney Disease. J Am Soc Nephrol 20: 1453-1464. doi: 10.1681/ASN.2008070692 |
[5] | Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112-119. doi: 10.1053/ajkd.1998.v32.pm9820470 |
[6] | Shroff RC, Shanahan CM (2007) The vascular biology of calcification. Semin Dial 20: 103-109. doi: 10.1111/j.1525-139X.2007.00255.x |
[7] | Thompson B, Towler DA (2012) Arterial Calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol 8: 529-543. doi: 10.1038/nrendo.2012.36 |
[8] | Cozzolino M, Dusso A, Slatopolsky E (2001) Role of Calcium- Phosphate Produce and Bone-Associated Proteins on Vascular Calcification in Renal Failure. J Am Soc Nephrol 12: 2511-2516. |
[9] | Ganesh SK, Stack AG, Levin NW, et al. (2001) Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138. |
[10] | Lagna G, Ku M, Nguyen P, et al. (2007) Control of Phenotypic Plasticity of Smooth Muscle Cells by Bone Morphogenetic Protein Signaling through the Myocardin-related Transcription factors. J Biol Chem 282: 37244-37255. doi: 10.1074/jbc.M708137200 |
[11] | Iyemere V, Proudfoot D, Weissberg P, et al. (2006) Vascular smooth muscle cell phenotypic plasticity and regulation of vascular calcification. J Intern Med 260: 192-210. doi: 10.1111/j.1365-2796.2006.01692.x |
[12] | Abedin M, Tintut Y, Demer L (2004) Mesenchymal Stem Cells and the Artery Wall. Circ Res 95: 671-676. doi: 10.1161/01.RES.0000143421.27684.12 |
[13] | Owens GF (1995) Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 75: 487-517. |
[14] | Cai T, Sun D, Duan Y, et al. (2016) Wnt/Beta catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulation Runx2 gene expression. Exp Cell Res 345: 206-217. doi: 10.1016/j.yexcr.2016.06.007 |
[15] | Huang H, Xi H (2008) Wnt/Beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol 20: 119-125. doi: 10.1016/j.ceb.2008.01.009 |
[16] | Li X, Warmington K, Niu Q, et al. (2010) Inhibition of Sclerostin by Monoclonal Antibody Increases Bone Formation, Bone Mass, and Bone Strength in Aged Male Rats. J Bone Miner Res 25: 2647-2656. |
[17] | Semenov M, Tamai K, He X (2005) Sost is a Ligand for LRP5/6 and a Wnt Signaling Inhibitor. J Biol Chem 280: 26770-26775. doi: 10.1074/jbc.M504308200 |
[18] | Byon CH, Chen Y (2015) Molecular Mechanisms of Vascular Calcification in Chronic Kidney Disease: The Link Between Bone and Vasculature. Curr Osteoporosis Rep 13: 206-215. doi: 10.1007/s11914-015-0270-3 |
[19] | Chavkin NW, Chia JJ, Crouthamel MH, et al. (2015) Phosphate uptake independent signaling functions of the type III sodium-dependent phosphate transporter, PiT-1, in vascular smooth muscle cells. Exp Cell Res 333: 39-48. doi: 10.1016/j.yexcr.2015.02.002 |
[20] | Crouthamel MH, Lau WL, Leaf EM, et al. (2013) Sodium-dependent phosphate cotransporters and phosphate-induced calcification of vascular smooth muscle cells: Redundant roles for PiT-1 and PiT-2. Arterioscler, Thromb, Vasc Biol 33: 2625-2632. doi: 10.1161/ATVBAHA.113.302249 |
[21] | Skalli O, Pelte M, Peclet M, et al. (1989) α-smooth muscle actin, a differenetitaion marker of smooth muscle cells, is present in microfilamentous bundles of pericytes. J Histochem Cytochem 37: 315-321. doi: 10.1177/37.3.2918221 |
[22] | Suen P, Qin L (2016) Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review. J Orthop Transl 4: 1-13. |
[23] | Shah A, Shoback D, Lewiecki E (2015) Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. Int J Women's Health 7: 565-580. |
[24] | Shu R, Bai D, Sheu T, et al. (2017) Sclerostin Promotes Bone Remodeling in the Process of Tooth Movement. Plos One 12: 1-16. |
[25] | Behets GJ, Viaene L, Meijers B, et al. (2017) Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD. Plos One 12: 1-12. |
[26] | Kirkpantur A, Balci M, Turkvatan A, et al. (2015) Independent association between serum sclerostin levels and carotid artery atherosclerosis in prevalent haemodialysis patients. Clin Kidney J 8: 737-743. doi: 10.1093/ckj/sfv077 |
[27] | Asamiya Y, Tsuchiya K, Nitta K (2016) Role of sclerostin in the pathogenesis of chronic kidney disease-mineral bone disorder. Ren Replace Ther 2: 1-8. doi: 10.1186/s41100-016-0016-4 |
[28] | Claes K, Viaene L, Heye S, et al. (2013) Sclerostin: Another Vascular Calcification Inhibitor? J Clin Endocrinol Metab 98: 3221-3228. doi: 10.1210/jc.2013-1521 |